Participant characteristics were similar between surgical treatment groups.
Get the latest treatment options for rectal cancer, including concurrent chemotherapy and radiotherapy and levoleucovorin plus 5-FU.
Risk of Brain Metastasis in Colorectal Cancer Dependent on Tumor Location and Other Metastatic SitesJune 22, 2018
In patients with colorectal cancer, rectal tumors and lung metastasis appeared to be linked to an elevated risk for brain cancer.
Adding Oxaliplatin to Capecitabine-Based Chemotherapy, Radiation May Not Improve Survival in Rectal CancerJune 19, 2018
Researchers randomly assigned 1090 patients with advanced rectal adenocarcinoma to 5 weeks of preoperative capecitabine-based chemoradiation followed by 6 cycles of capecitabine alone or with oxaliplatin.
After a median follow-up of 3.1 years, patients who received adjuvant chemotherapy had improved rates of survival.
Investigators enrolled 98 patients to receive preoperative treatment with intravenous panitumumab plus concurrent radiotherapy.
Incomplete neoadjuvant radiotherapy is associated with worse overall survival in patients with locally advanced rectal cancer.
Compared with adults born in around 1950, those born around 1990 are at a 2-fold higher risk for colon cancers and a 4-fold higher risk for rectal cancers.
Among patients with rectal cancer, delaying surgery following short-course radiotherapy yields similar outcomes.
Radiation oncologists in the US are less likely to offer neoadjuvant short-course radiotherapy over long-course chemoradiotherapy.
Neoadjuvant chemotherapy (NCRT) is superior to neoadjuvant multi-agent chemotherapy (NMAC) for the treatment of stage II or III rectal adenocarcinoma.
Adjuvant chemotherapy is beneficial for patients with locally-advanced, postoperative rectal cancer.
Oxaliplatin-based preoperative chemoradiotherapy may yield more pathological complete responses (pCR) for locally-advanced rectal cancer.
Some patients with rectal cancer who experience complete clinical response after neoadjuvant therapy may safely avoid total mesorectal excision.
Metastatic colorectal cancer with the primary tumor located on the left side of the colon is associated with longer survival.
Single nucleotide polymorphism (SNP) IL17F-rs9463772 represents a prognostic marker of long-term survival in locally advanced rectal cancer.
Platelet counts at the time of initial diagnosis had prognostic value for patients with rectal adenocarcinoma receiving neoadjuvant treatment.
Long-course oxaliplatin-based preoperative chemoradiation was similarly efficacious in patients with cT4 or fixed cT3 rectal cancer
Best length of time to wait to perform surgery for rectal cancer after chemotherapy and radiation treatment.
A substantial proportion of patients with rectal cancer managed by the watch-and-wait approach avoided a major operation.
Capecitabine should be considered a standard of care in the pre-operative rectal cancer setting.
Neoadjuvant chemoradiotherapy followed by local excision may be an organ-preserving alternative in certain patients with clinical T2N0 rectal cancer.
Two studies found that laparoscopic surgery for rectal cancer found that it was potentially inferior to open-surgery.
Aspirin might have anticancer activity against rectal cancer during preoperative chemoradiation.
Older patients seem to face similar outcomes as younger patients when treated with neoadjuvant chemoradiation for rectal cancer.
Standard combined modality treatment for locally advanced rectal cancer had less disease-free survival than a new CRO/ARO/AIO-04 regimen.
Cumulative exposure to statins after a diagnosis of colorectal cancer was associated with lower overall mortality.
Single nucleotide polymorphism in the let-7 complementary site 6 of KRAS mRNA may be a response biomarker in colorectal cancer.
Investigators recommend prioritized screening in certain pockets of the U.S. that are statistically identified as colorectal cancer (CRC) death hotspots.
Greater progress in reducing colorectal cancer incidence, mortality rates observed in Northeastern states compared to Southern states.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- CAR-T Trial for Triple-Negative Breast Cancer Under Way
- Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma
- Adjuvant Trastuzumab Emtansine Confers Improved Outcome in KATHERINE Trial
- Phase 3 GEICAM/CIBOMA Results: Adjuvant Capecitabine in Triple-Negative Breast Cancer
- Extension of Adjuvant Anastrozole Regimen to 10 Years Yields Higher DFS, but Not OS
- Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma
- Younger Breast Cancer Patients at Higher Risk for Osteoporosis
- Molecular Mechanisms Underlying Immunosurveillance in Multiple Myeloma Identified
- Gly101Val Mutation Directly Causes Resistance to Venetoclax
- Can Treatments for Childhood ALL Alter the Gut Microbiome?